DEFB110
Beta-defensin 110
Also known as: DB110_HUMAN, DEFB-10, DEFB-11, DEFB111
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q30KQ9
- Gene
- DEFB110
- Ensembl
- ENSG00000203970
- Chromosome
- 6
- Canonical length
- 67 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils. Defensins are short, processed peptide molecules that are classified by structure into three groups: alpha-defensins, beta-defensins and theta-defensins. All beta-defensin genes are densely clustered in four to five syntenic chromosomal regions. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2014]
Canonical amino-acid sequenceUniProt
67 residues, UniProt reviewed canonical sequence.
>Q30KQ9|DEFB110
1 MKIQLFFFIL HFWVTILPAK KKYPEYGSLD LRRECRIGNG QCKNQCHENE IRIAYCIRPG
61 THCCLQQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DEFB110 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 821 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 821 nTPM
- seminal vesicle: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
Single-cell type
- epididymal principal cells: 495 nCPM
- epididymal clear cells: 10 nCPM
- epididymal basal cells: 6.5 nCPM
- mast cells: 1.2 nCPM
- epididymal efferent duct absorptive cells: 0.7 nCPM
- t-cells: 0.6 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.2 nTPM
- pons: 0.2 nTPM
- midbrain: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.92
- gnomAD pLI
- 0.02
- gnomAD missense Z
- -0.85
- DepMap mean gene effect
- 0.13
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DEFB110 as an antibody target. Whether an autoantibody or antibody against DEFB110 could matter depends on whether native DEFB110 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DEFB110 is annotated as secreted, so native DEFB110 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label DEFB110 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...